Body mass index and phenotype in subjects with mild-to-moderate persistent asthma

被引:108
|
作者
Sutherland, E. Rand [1 ,2 ]
Lehman, Erik B. [3 ]
Teodorescu, Mihaela [4 ]
Wechsler, Michael E. [5 ,6 ]
机构
[1] Natl Jewish Hlth, Denver, CO 80206 USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] Penn State Univ, Dept Hlth Evaluat Sci, Hershey, PA USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Sleep Inst, Sect Allergy Pulm & Crit Care Med,Dept Med, Madison, WI 53706 USA
[5] Brigham & Womens Hosp, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
Asthma; obesity; treatment; severity; RANDOMIZED CONTROLLED TRIAL; CLINICAL-RESEARCH NETWORK; OBSTRUCTIVE SLEEP-APNEA; INHALED CORTICOSTEROIDS; PULMONARY-FUNCTION; NOCTURNAL ASTHMA; OBESITY; WOMEN; EPIDEMIOLOGY; ASSOCIATION;
D O I
10.1016/j.jaci.2009.04.005
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Although obesity has been hypothesized to worsen asthma, data from studies of subjects with well-characterized asthma are lacking. Objective: We sought to evaluate the relationship between body mass index (BMI), asthma impairment, and response to therapy. Methods: BMI (in kilograms per meter squared) and asthma phenotypic and treatment response data were extracted from Asthma Clinical Research Network studies. The cross-sectional relationship between BMI and asthma impairment was analyzed, as was the longitudinal relationship between BMI and response to asthma controller therapies. Results: One thousand two hundred sixty-five subjects with mild-to-moderate persistent asthma were evaluated. Analyses of lean versus overweight/obese asthmatic subjects demonstrated small differences in FEV(1) (3.05 vs 2.91 L, P = .001), FEV(1)/forced vital capacity ratio (mean, 83.5% vs 82.4%; P = .01), rescue albuterol use (1.1 vs 1.2 puffs per day, P = .03), and asthma-related quality of life (5.77 vs 5.59, P = .0004). Overweight/obese asthmatic subjects demonstrated a smaller improvement in exhaled nitric oxide levels with inhaled corticosteroid (ICS) treatment than did lean asthmatic subjects (3.6 vs 6.5 ppb, P = .04). With ICS/long-acting beta-agonist treatment, overweight/obese asthmatic subjects demonstrated smaller improvements in lung function than lean asthmatic subjects, with an 80 mL (P = .04) and 1.7% (P = .02) lesser improvement in FEV(1) and FEV(1)/forced vital capacity ratio, respectively. Significant differences in therapeutic response to leukotriene modifiers between BMI categories were not observed. Conclusions: Increased BMI is not associated with clinically significant worsening of impairment in subjects with mild-to-moderate persistent asthma. There is a modest association between increased BMI and reduced therapeutic effect of ICS-containing regimens in this patient population. Prospective studies evaluating the effect of being overweight or obese on treatment response in asthma are warranted. (J Allergy Clin Immunol 2009;123:1328-34.)
引用
收藏
页码:1328 / 1334
页数:7
相关论文
共 50 条
  • [1] Obesity And Disease Phenotypes In Mild-To-Moderate Persistent Asthma
    Stream, A.
    Lehman, E.
    King, T.
    Sutherland, E. R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [2] The role of budesonide in adults and children with mild-to-moderate persistent asthma
    Banov, CH
    [J]. JOURNAL OF ASTHMA, 2004, 41 (01) : 5 - 17
  • [3] Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma
    Zeiger, RS
    Szefler, SJ
    Phillips, BR
    Schatz, M
    Martinez, FD
    Chinchilli, VM
    Lemanske, RF
    Strunk, RC
    Larsen, G
    Spahn, JD
    Bacharier, LB
    Bloomberg, GR
    Guilbert, TW
    Heldt, G
    Morgan, WJ
    Moss, MH
    Sorkness, CA
    Taussig, LM
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (01) : 45 - 52
  • [4] Effect of treating allergic rhinitis with corticosteroids in patients with mild-to-moderate persistent asthma
    Stelmach, R
    Nunes, MDT
    Ribeiro, M
    Cukier, A
    [J]. CHEST, 2005, 128 (05) : 3140 - 3147
  • [5] Impact of montelukast on symptoms in mild-to-moderate persistent asthma and exercise-induced asthma: Results of the ASTHMA survey
    Malonne, H
    Lachman, A
    Van den Brande, P
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (08) : 512 - 519
  • [6] Uncontrolled mild-to-moderate asthma may not be mild or moderate, or even asthma: The benefits of early phenotyping
    Melhorn, James
    Lavoie, Gabriel
    [J]. RESPIROLOGY, 2024,
  • [7] Bronchoalveolar lavage in asthmatic children: Evidence of neutrophil activation in mild-to-moderate persistent asthma
    Barbato, A
    Panizzolo, C
    Gheno, M
    Sainati, L
    Favero, E
    Faggian, D
    Giusti, F
    Pesscolderungg, L
    La Rosa, M
    [J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2001, 12 (02) : 73 - 77
  • [8] Characterization of glucocorticosteroid response in mild-to-moderate asthma
    Zijlstra, G. J.
    Volbeda, F.
    Postma, D. S.
    Boezen, H. M.
    Lodewijk, M. E.
    Hylkema, M. N.
    Timens, W.
    Ten Hacken, N. H. T.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [9] Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma
    Galant, SP
    van Bavel, J
    Finn, A
    Gross, G
    Pleskow, W
    Brown, A
    Hamedani, AG
    Harding, SM
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (03) : 273 - 280
  • [10] Efficacy and safety evaluation of ciclesonide in mild-to-moderate persistent asthma previously treated with inhaled corticosteroids
    Meltzer, Eli O.
    Korenblat, Phillip E.
    Weinstein, Steven F.
    Noonan, Michael
    Karafilidis, John
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2009, 30 (03) : 293 - 303